GLPBio

PROTAC CARM1 degrader-1 TFA

Catalog No.: GC81882Purity:>98.00%
PROTAC CARM1 degrader-1 TFA is a highly selective CARM1 PROTAC degrader, with a DC50 of 8.1 nM in MCF‑7 cells.

Products are for research use only. Not for human use. We do not sell to patients.


PROTAC CARM1 degrader-1 TFA
500μgIn Stock
$468.00
1

Citations

No citations are currently available for this product. Below are selected publications citing GlpBio products.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

PROTAC CARM1 degrader-1 TFA is a highly selective CARM1 PROTAC degrader, with a DC50 of 8.1 nM in MCF‑7 cells. PROTAC CARM1 degrader-1 TFA recruits the VHL E3 ubiquitin ligase complex to act on CARM1, inducing a proteasome-dependent degradation process. PROTAC CARM1 degrader-1 TFA downregulates the methylation level of CARM1 substrates in breast cancer cells, inhibits breast cancer cell migration, and exhibits no significant inhibitory effect on cell proliferation. PROTAC CARM1 degrader-1 TFA is applicable for related research on breast cancer [1]. (Pink: CARM1 ligand; Blue: VHL ligand; Black: linker).

In Vitro, PROTAC CARM1 degrader-1 (Compound 3b) (0.01‑500 nM; 24 h) TFA potently induces the degradation of CARM1 protein in MCF‑7 cells (DC50 = 8.1 nM, Dmax = 97%), and exhibits high selectivity over PRMT1, PRMT5, and PRMT6; moreover, the CARM1 degradation activity is abolished upon co-treatment with MG132, MLN4924, VH-032 or TP-064 [1]. PROTAC CARM1 degrader-1 (0.5 μM; 48 h) TFA downregulates the asymmetric dimethylation modification of the CARM1 substrates BAF155 and PABP1 in MCF‑7 cells[1]. PROTAC CARM1 degrader-1 (0.5 μM; 20 h) TFA exerts a significant migration inhibitory effect on MDA-MB-231 triple-negative breast cancer cells, with no apparent anti-proliferative activity[1].

References:
[1]. Xie H, et al. Development of Potent and Selective Coactivator-Associated Arginine Methyltransferase 1 (CARM1) Degraders. Journal of medicinal chemistry. 2023 Sep 28;66(18):13028-13042.

Product Documents

Purity:>98.00%Appearance:A solid

Chemical Properties

Molecular Formula
C73H99F3N12O10S
Molecular Weight
1393.7
Solubility
DMSO: 100 mg/mL (71.75 mM; Need ultrasonic)
Storage
Store at 4°C, sealed storage, away from moisture and light
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for PROTAC CARM1 degrader-1 TFA

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%